Takara Bio Past Earnings Performance
Past criteria checks 1/6
Takara Bio has been growing earnings at an average annual rate of 8.1%, while the Biotechs industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 11.7% per year. Takara Bio's return on equity is 0.1%, and it has net margins of 0.3%.
Key information
8.1%
Earnings growth rate
8.1%
EPS growth rate
Biotechs Industry Growth | 31.9% |
Revenue growth rate | 11.7% |
Return on equity | 0.1% |
Net Margin | 0.3% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Takara Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 42,822 | 114 | 16,067 | 7,790 |
31 Mar 24 | 43,505 | 1,480 | 15,581 | 8,324 |
31 Dec 23 | 47,670 | 1,571 | 16,153 | 8,827 |
30 Sep 23 | 64,671 | 8,558 | 16,108 | 8,963 |
30 Jun 23 | 73,216 | 12,424 | 15,798 | 8,956 |
31 Mar 23 | 78,142 | 16,012 | 15,649 | 8,575 |
31 Dec 22 | 82,246 | 20,080 | 15,167 | 7,956 |
30 Sep 22 | 68,735 | 18,378 | 14,789 | 7,303 |
30 Jun 22 | 66,529 | 17,731 | 14,514 | 6,674 |
31 Mar 22 | 67,699 | 19,849 | 14,200 | 6,109 |
31 Dec 21 | 62,196 | 18,185 | 13,664 | 5,909 |
30 Sep 21 | 60,244 | 17,282 | 13,257 | 5,801 |
30 Jun 21 | 54,420 | 15,168 | 12,835 | 5,667 |
31 Mar 21 | 46,086 | 9,547 | 12,374 | 5,545 |
31 Dec 20 | 39,556 | 6,837 | 11,585 | 4,713 |
30 Sep 20 | 35,508 | 4,018 | 11,189 | 4,414 |
30 Jun 20 | 32,853 | 2,632 | 11,063 | 4,102 |
31 Mar 20 | 34,565 | 3,819 | 10,961 | 3,869 |
31 Dec 19 | 34,511 | 4,277 | 10,666 | 3,985 |
30 Sep 19 | 34,921 | 4,012 | 10,736 | 4,091 |
30 Jun 19 | 35,644 | 4,216 | 10,804 | 4,262 |
31 Mar 19 | 35,841 | 3,657 | 10,884 | 4,337 |
31 Dec 18 | 35,554 | 3,355 | 10,919 | 4,400 |
30 Sep 18 | 35,556 | 3,753 | 10,779 | 4,460 |
30 Jun 18 | 34,804 | 3,345 | 10,504 | 4,564 |
31 Mar 18 | 32,312 | 2,335 | 10,446 | 4,653 |
31 Dec 17 | 31,376 | 859 | 10,499 | 4,648 |
30 Sep 17 | 30,302 | 987 | 10,052 | 4,494 |
30 Jun 17 | 29,424 | 1,089 | 10,068 | 4,254 |
31 Mar 17 | 29,375 | 1,352 | 9,648 | 4,101 |
31 Dec 16 | 29,668 | 2,282 | 9,394 | 4,027 |
30 Sep 16 | 29,671 | 1,856 | 9,545 | 4,096 |
30 Jun 16 | 30,274 | 1,655 | 9,460 | 4,205 |
31 Mar 16 | 29,729 | 1,334 | 9,380 | 4,275 |
31 Dec 15 | 29,382 | 1,660 | 9,063 | 4,294 |
30 Sep 15 | 28,255 | 704 | 8,671 | 4,082 |
30 Jun 15 | 26,951 | 909 | 8,325 | 3,718 |
31 Mar 15 | 25,969 | 963 | 8,123 | 3,401 |
31 Dec 14 | 25,031 | 844 | 7,975 | 3,097 |
30 Sep 14 | 24,599 | 1,647 | 7,863 | 3,021 |
30 Jun 14 | 24,514 | 1,742 | 7,721 | 3,025 |
31 Mar 14 | 23,905 | 1,470 | 7,593 | 3,026 |
31 Dec 13 | 22,815 | 1,291 | 7,240 | 2,876 |
30 Sep 13 | 21,828 | 1,375 | 7,034 | 2,812 |
Quality Earnings: 4974 has a large one-off loss of ¥556.0M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 4974's current net profit margins (0.3%) are lower than last year (17%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4974's earnings have grown by 8.1% per year over the past 5 years.
Accelerating Growth: 4974's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4974 had negative earnings growth (-99.1%) over the past year, making it difficult to compare to the Biotechs industry average (172.6%).
Return on Equity
High ROE: 4974's Return on Equity (0.1%) is considered low.